Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Analysts

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $7.40.

Several equities analysts have commented on the company. Stephens reiterated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its stake in Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after acquiring an additional 7,525 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Actinium Pharmaceuticals in the 2nd quarter valued at about $92,000. Bank of New York Mellon Corp lifted its holdings in Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares during the period. Renaissance Technologies LLC bought a new position in Actinium Pharmaceuticals in the second quarter valued at approximately $142,000. Finally, Interchange Capital Partners LLC acquired a new stake in Actinium Pharmaceuticals during the 3rd quarter worth $37,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

ATNM opened at $1.39 on Wednesday. The company has a market cap of $43.36 million, a P/E ratio of -1.00 and a beta of 0.12. The business’s 50-day moving average is $1.44. Actinium Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $10.24.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).